Laboratorios Rubió is a company that is currently
undergoing a process of expansion and growth
Revenue (in thousands of €)
Laboratorios Rubió is a company that is currently undergoing a process of expansion and growth. In the last 5 years, the continued advances are an indication of the hard work put in, and the implementation of a strategy (2015-2019) that shifts the focus towards identifying new business segments, opening new markets and signing distribution agreements with other companies in the pharmaceutical sector.
In 2018, revenue reached € 40,9 million, which is 17,1% more than in 2017. By market, the increase in Spain was one of 22%, with 1,9% growth in exports.
If we compare 2018 with the 2015 period, the increase in revenue is 35,9%, with 41,6% corresponding to the national market, and 18,2% to the international market.
The growth we hope to achieve in 2019 is 9,2%, which is brought about by sales in the national market.
The company’s staff is made up of 150 people—11,3% more than in 2015—with the greatest amount of growth happening in the sales and industrial operations departments.
Laboratorios Rubió is a company that places its trust in the people who make up its organisation, recognises their professional value and dedicates resources to ensure that a good working environment is maintained by fostering opportunities, personal development and a good work-life balance.
In the last 5 years, including the 2018 budget, total investment reached € 10,8 million, of which € 5.8 million are industrial investments, € 834 thousand have been invested in to IT and new technology and € 4,88 million into different projects such as the development of new pharmaceutical formulations, sales agreements in Europe and the USA, and the LiposCale.
Investments (in thousands of €)
Created in 2014, this subsidiary acts as a “patent box” in order to boost the Laboratorios Rubió’s R&D&i department. Within this sphere of activity, the company’s number one strategy is based on expanding the lifecycle of their own products, collaborating in new research programmes whose goals tie in with the company’s own therapeutic goals, and establishing strategic alliances with research foundations in related fields.
Biosfer Teslab, a spin-off of the Universidad Rovira i Virgili (URV) and the Institut d’Investigació Sanitària Pere Virgili (IISPV), is one of Laboratorios Rubió’s investee companies, which specialises in developing in vitro diagnostic tests to improve cardiovascular assessment in high-risk patients.